News

Clinical Trials Arena on MSN6d
MaaT Pharma reports safety interim analysis from trial of microbiome therapy
French biotechnology company MaaT Pharma has reported positive results from an interim safety analysis of its Phase IIb ...
Availability of MaaT Pharma’s 2024 Universal Registration Document (URD)
Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the ...
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of ...
MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving ...
Kepler Capital Sticks to Their Buy Rating for MaaT Pharma (MAAT)
Kepler Capital analyst Christophe dombu maintained a Buy rating on MaaT Pharma (MAAT – Research Report) on April 8 and set a price target of ...
Morningstar11d
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival.
Kepler Capital Keeps Their Buy Rating on MaaT Pharma (MAAT)
Kepler Capital analyst Christophe dombu maintained a Buy rating on MaaT Pharma (MAAT – Research Report) on April 2 and set a price target of ...